PepGen (NASDAQ:PEPG) Issues Earnings Results

PepGen (NASDAQ:PEPG) issued its earnings results on Monday. The company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.81) by $0.13, Zacks reports.

PepGen Trading Up 67.2 %

Shares of NASDAQ:PEPG opened at $2.29 on Tuesday. The stock has a market capitalization of $74.65 million, a PE ratio of -0.77 and a beta of 1.53. PepGen has a 1 year low of $1.16 and a 1 year high of $19.30. The firm has a fifty day moving average price of $2.51 and a 200 day moving average price of $5.83.

Analyst Upgrades and Downgrades

PEPG has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of PepGen in a report on Monday. Wedbush cut their price target on PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research note on Friday, November 8th. Finally, Bank of America cut PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price target for the company. in a research note on Monday, December 16th.

About PepGen

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.